HB1316 requires health benefit plans offered, issued, renewed, delivered, or extended in Arkansas on and after January 1, 2026, to cover lung cancer screenings and related follow-up services in accordance with American Cancer Society guidelines. The bill defines the health plans and insurers covered, and it expressly includes private insurance products as well as state-supported programs such as Arkansas Medicaid, the Arkansas Health and Opportunity for Me Program, and the State and Public School Life and Health Insurance Program.
The bill also specifies that this screening coverage may not be subject to an annual deductible, copayment, or coinsurance limit, and that the benefit cannot reduce other covered benefits. It directs the Insurance Commissioner, the Department of Human Services, and the State Board of Finance to adopt rules as needed to implement the new coverage requirements for the insurance market and applicable public programs.
Impact
HB1316 amends Arkansas Code Title 23, Chapter 79 by adding a new subchapter on coverage for lung cancer screenings. Its practical effect is to create a statewide insurance mandate for low-dose CT lung cancer screening and follow-up care, expanding coverage obligations for private insurers and certain public health benefit programs. The bill also requires administrative rulemaking by state agencies to align Medicaid, ARHOME, and state employee/public school plans with the new mandate.
Sentiment
The bill appears to have broad legislative support and little visible opposition. It passed the House 82-6 and the Senate 33-0 on third reading, indicating strong bipartisan approval. The findings section frames the measure as a public health priority, emphasizing Arkansas’s high lung cancer burden, low screening rates, and the potential for early detection to save lives.
Contention
The main policy issues embedded in the bill concern cost, coverage standards, and implementation. By requiring first-dollar coverage with no deductible or copay, the bill shifts screening costs to insurers and public programs, which may raise premium or budget concerns even though no debate transcript is available here. Another point of potential contention is the use of American Cancer Society guidelines rather than other screening standards, which could affect eligibility and coverage scope. The bill also highlights rural access, transportation barriers, and the need for provider capacity, suggesting implementation challenges in underserved areas.